A Case Report of a Pregnant Woman With Type 2 Diabetes Mellitus Using Dulaglutide During the First Trimester of Pregnancy

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 9
• Main Authors: Alghamdi, Adel, Alsaeddi, Abeer, Malki, Hashem, Alsaedi, Ameerah
• Format: Journal Article
• Language: English
• Published: Palo Alto Cureus Inc 04-09-2023; Cureus
• Subjects: Abdomen; Antidiabetics; Biometrics; Case reports; Diabetes; Endocrinology; Endocrinology/Diabetes/Metabolism; FDA approval; Fetuses; Gestational age; Glucose; Obstetrics/Gynecology; Overweight; Pregnancy; Women
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.44644

Among women of childbearing age, type 2 diabetes mellitus (T2DM) is becoming more prevalent, increasing the likelihood of abortion, congenital anomalies, and neonatal death. Dulaglutide has not been adequately studied to determine if it causes birth defects or miscarriages during pregnancy. According to animal studies, the fetus is at risk from the use of dulaglutide during pregnancy. We report the case of a 39-year-old woman with T2DM who used dulaglutide (1.5 mg/week) along with glargine and aspart before conception. During the third month of pregnancy, she was seen in the clinic for the first time during which dulaglutide was stopped and basal-bolus insulin therapy was retained with dosing titration. The newborn was a male with a normal birth weight for his gestational age. Dulaglutide did not affect development. No minor or major malformations were noted in the fetus except for mild bilateral renal pyelectasis. Moreover, no maternal or fetal complications were observed. It is not possible to ascertain the safety of glucagon-like peptide-1 receptor agonists in pregnancy, despite the normal outcome in the present pregnancy; however, the data described here may be of value in further considering this issue.